PMID- 35668198 OWN - NLM STAT- MEDLINE DCOM- 20220715 LR - 20220719 IS - 1432-0584 (Electronic) IS - 0939-5555 (Linking) VI - 101 IP - 8 DP - 2022 Aug TI - Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study. PG - 1835-1841 LID - 10.1007/s00277-022-04877-w [doi] AB - Chemotherapy-induced nausea and vomiting (CINV) is common in patients with lymphoma and multiple myeloma (MM) receiving high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT). Despite a standard triple antiemetic regimen of a neurokinin-1 (NK1) receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone is recommended, how to control the protracted CINV in ASCT setting remains an intractable problem. Here, we retrospectively analyze CINV data of 100 patients who received either SEAM (semustine, etoposide, cytarabine, melphalan) or MEL140-200 (high-dose melphalan) before ASCT, evaluate the efficacy and safety of multiple-day administration of fosaprepitant combined with tropisetron and olanzapine (FTO), and compare the results to those of patients who received a standard regimen of aprepitant, tropisetron, and dexamethasone (ATD). The overall rate of complete response (CR), defined as no emesis and no rescue therapy, is 70% in the FTO group compared to 36% in the ATD group. Although CR rates are comparable in the acute phase between the two groups, significantly more patients treated by FTO achieve CR in the delayed phase than those treated by ATD (74% vs. 38%, p < 0.001). Moreover, FTO treatment significantly reduced the percentage of patients who are unable to eat, as well as the requirement for rescue medications. Both regimens are well tolerated and most adverse events (AEs) were generally mild and transient. In conclusion, the antiemetic strategy containing multiple-day administration of fosaprepitant is safe and effective for preventing CINV in lymphoma and MM patients, particularly in the delayed phase. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Ye, Peipei AU - Ye P AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Pei, Renzhi AU - Pei R AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Wang, Tiantian AU - Wang T AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Cao, Junjie AU - Cao J AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Zhang, Pisheng AU - Zhang P AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Chen, Dong AU - Chen D AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Liu, Xuhui AU - Liu X AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Du, Xiaohong AU - Du X AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Li, Shuangyue AU - Li S AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Tang, Shanhao AU - Tang S AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Hu, Youqian AU - Hu Y AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. FAU - Jiang, Lei AU - Jiang L AUID- ORCID: 0000-0002-8676-8859 AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. jianglei@nbu.edu.cn. AD - Department of Pathology, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, 315211, China. jianglei@nbu.edu.cn. FAU - Lu, Ying AU - Lu Y AD - Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315101, China. 814871416@qq.com. LA - eng PT - Journal Article DEP - 20220606 PL - Germany TA - Ann Hematol JT - Annals of hematology JID - 9107334 RN - 0 (Antiemetics) RN - 0 (Antineoplastic Agents) RN - 0 (Morpholines) RN - 6I819NIK1W (Tropisetron) RN - 6L8OF9XRDC (fosaprepitant) RN - 7S5I7G3JQL (Dexamethasone) RN - N7U69T4SZR (Olanzapine) RN - Q41OR9510P (Melphalan) SB - IM MH - *Antiemetics/therapeutic use MH - *Antineoplastic Agents/therapeutic use MH - Dexamethasone MH - *Hematopoietic Stem Cell Transplantation MH - Humans MH - *Lymphoma/drug therapy MH - Melphalan MH - Morpholines/therapeutic use MH - *Multiple Myeloma/drug therapy MH - Nausea/chemically induced/prevention & control MH - *Olanzapine/therapeutic use MH - Retrospective Studies MH - *Transplantation Conditioning/adverse effects MH - Transplantation, Autologous MH - *Tropisetron/therapeutic use MH - Vomiting/chemically induced/prevention & control OTO - NOTNLM OT - Autologous stem cell transplantation OT - Chemotherapy-induced nausea and vomiting OT - Fosaprepitant OT - Olanzapine EDAT- 2022/06/07 06:00 MHDA- 2022/07/16 06:00 CRDT- 2022/06/06 23:22 PHST- 2021/11/21 00:00 [received] PHST- 2022/05/29 00:00 [accepted] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/07/16 06:00 [medline] PHST- 2022/06/06 23:22 [entrez] AID - 10.1007/s00277-022-04877-w [pii] AID - 10.1007/s00277-022-04877-w [doi] PST - ppublish SO - Ann Hematol. 2022 Aug;101(8):1835-1841. doi: 10.1007/s00277-022-04877-w. Epub 2022 Jun 6.